A. Wylie

发表

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.

F. Lombardo, D. Fabbro, W. Jahnke, 2018, Journal of medicinal chemistry.

The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo

James R. Porter, K. West, J. Adams, 2009, Molecular Cancer Therapeutics.

Novel imprinted DLK1/GTL2 domain on human chromosome 14 contains motifs that mimic those implicated in IGF2/H19 regulation.

S. Murphy, R. Jirtle, T. Orton, 2000, Genome research.

Epigenetic detection of human chromosome 14 uniparental disomy

L. Shaffer, S. Murphy, V. Sutton, 2003, Human mutation.

Animal Model Tissue-Specific Inactivation of Murine M6P/IGF2R

R. Waterland, R. Jirtle, T. Orton, 2003 .

Tissue-specific inactivation of murine M6P/IGF2R.

R. Waterland, R. Jirtle, T. Orton, 2003, The American journal of pathology.

Regulated expression of a foreign gene targeted to the ischaemic myocardium.

K. Webster, D. J. Discher, N. Bishopric, 1997, Cardiovascular research.

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

C. Emery, S. Roman-Roman, Ensar Halilovic, 2016, Oncotarget.

Novel Imprinted DLK 1 / GTL 2 Domain on Human Chromosome 14 Contains Motifs that Mimic Those Implicated in IGF 2 / H 19 Regulation

S. Murphy, R. Jirtle, T. Orton, 2000 .

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Hans Bitter, Franco Lombardo, Joseph Schoepfer, 2017, Nature.

Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors.

S. Peluso, K. West, V. Palombella, 2012, Journal of medicinal chemistry.

The neuronatin gene resides in a "micro-imprinted" domain on human chromosome 20q11.2.

S. Murphy, R. Jirtle, A. Wylie, 2001, Genomics.

Divergent evolution in M6P/IGF2R imprinting from the Jurassic to the Quaternary.

A. Hoffman, T. Vu, J. Killian, 2001, Human molecular genetics.

Imprinting of PEG3, the human homologue of a mouse gene involved in nurturing behavior.

S. Murphy, R. Jirtle, A. Wylie, 2001, Genomics.

Genomic imprinting: implications for human disease.

R. Jirtle, D. Pulford, A. Wylie, 1999, The American journal of pathology.

Abstract 1891: Pharmacological target validation studies of fatty acid synthase in carcinoma using the potent, selective and orally bioavailable inhibitor IPI-9119.

Lawrence W. C. Chan, M. Loda, S. Peluso, 2013 .

The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models

K. Robison, K. West, V. Palombella, 2011, Oncogene.

Exclusion of maternal uniparental disomy of chromosome 14 in patients referred for Prader-Willi syndrome using a multiplex methylation polymerase chain reaction assay

S. Murphy, R. Jirtle, K. Rauen, 2003, Journal of medical genetics.

Imaging the Intracellular Distribution of Tyrosine Kinase Inhibitors in Living Cells with Quantitative Hyperspectral Stimulated Raman Scattering

Dan Fu, Andrew Wylie, X. Xie, 2014, Nature chemistry.

Abnormal postnatal maintenance of elevated DLK1 transcript levels in callipyge sheep

Susan K. Murphy, S. Murphy, R. Jirtle, 2005, Mammalian Genome.

Identification of the single base change causing the callipyge muscle hypertrophy phenotype, the only known example of polar overdominance in mammals.

S. Murphy, J. Keele, S. Rhodes, 2002, Genome research.

Overdominance in Mammals Muscle Hypertrophy Phenotype , the Only Known Example of Polar Identification of the Single Base Change Causing the Callipyge

S. Murphy, J. Keele, S. Rhodes, 2002 .

PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma

A. Nicolas, S. Roman-Roman, S. Piperno-Neumann, 2019, Cancers.

ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia

W. Sellers, F. Lombardo, W. Jahnke, 2014 .

Review Genomic Imprinting: Implications for Human Disease

R. Jirtle, D. Pulford, A. Wylie, 2010 .

Development of KSQ-4279 as a first-in-class USP1 inhibitor for the treatment of BRCA-deficient cancers

F. Stegmeier, M. Schlabach, S. Shenker, 2020 .

Identification of the single base change causing the callipyge muscle hypertrophy phenotype, the only known example of polar overdominance in mammals.

S. Murphy, J. Keele, S. Rhodes, 2002, Genome research.